Based on in vitro studies, another extension of Ivacaftor has been recently approved by FDA to include CFTR gene mutations with residual function (RF), totalizing 28 eligible CF-causing mutations and increasing the number of patients who may benefit from Ivacaftor treatment [20]. Here, CFTR is linked to cystic fibrosis.